Literature DB >> 25448043

Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy.

Rik Ossenkoppele1, Daniel R Schonhaut, Suzanne L Baker, James P O'Neil, Mustafa Janabi, Pia M Ghosh, Miguel Santos, Zachary A Miller, Brianne M Bettcher, Maria L Gorno-Tempini, Bruce L Miller, William J Jagust, Gil D Rabinovici.   

Abstract

Determining the relative contribution of amyloid plaques and neurofibrillary tangles to brain dysfunction in Alzheimer disease is critical for therapeutic approaches, but until recently could only be assessed at autopsy. We report a patient with posterior cortical atrophy (visual variant of Alzheimer disease) who was studied using the novel tau tracer [(18) F]AV-1451 in conjunction with [(11) C]Pittsburgh compound B (PIB; amyloid) and [(18) F]fluorodeoxyglucose (FDG) positron emission tomography. Whereas [(11) C]PIB bound throughout association neocortex, [(18) F]AV-1451 was selectively retained in posterior brain regions that were affected clinically and showed markedly reduced [(18) F]FDG uptake. This provides preliminary in vivo evidence that tau is more closely linked to hypometabolism and symptomatology than amyloid.
© 2014 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25448043      PMCID: PMC4382124          DOI: 10.1002/ana.24321

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  20 in total

1.  Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  Amyloid imaging in dementias with atypical presentation.

Authors:  David A Wolk; Julie C Price; Charles Madeira; Judy A Saxton; Beth E Snitz; Oscar L Lopez; Chester A Mathis; William E Klunk; Steven T DeKosky
Journal:  Alzheimers Dement       Date:  2012-01-30       Impact factor: 21.566

3.  Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.

Authors:  David T Chien; Shadfar Bahri; A Katrin Szardenings; Joseph C Walsh; Fanrong Mu; Min-Ying Su; William R Shankle; Arkadij Elizarov; Hartmuth C Kolb
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

4.  Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.

Authors:  Rik Ossenkoppele; Marissa D Zwan; Nelleke Tolboom; Danielle M E van Assema; Sofie F Adriaanse; Reina W Kloet; Ronald Boellaard; Albert D Windhorst; Frederik Barkhof; Adriaan A Lammertsma; Philip Scheltens; Wiesje M van der Flier; Bart N M van Berckel
Journal:  Brain       Date:  2012-05-03       Impact factor: 13.501

5.  Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden.

Authors:  Gil D Rabinovici; Ansgar J Furst; Adi Alkalay; Caroline A Racine; James P O'Neil; Mustafa Janabi; Suzanne L Baker; Neha Agarwal; Stephen J Bonasera; Elizabeth C Mormino; Michael W Weiner; Maria L Gorno-Tempini; Howard J Rosen; Bruce L Miller; William J Jagust
Journal:  Brain       Date:  2010-01-15       Impact factor: 13.501

6.  Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease.

Authors:  Manja Lehmann; Pia M Ghosh; Cindee Madison; Robert Laforce; Chiara Corbetta-Rastelli; Michael W Weiner; Michael D Greicius; William W Seeley; Maria L Gorno-Tempini; Howard J Rosen; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  Brain       Date:  2013-01-28       Impact factor: 13.501

Review 7.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

8.  Distribution volume ratios without blood sampling from graphical analysis of PET data.

Authors:  J Logan; J S Fowler; N D Volkow; G J Wang; Y S Ding; D L Alexoff
Journal:  J Cereb Blood Flow Metab       Date:  1996-09       Impact factor: 6.200

9.  Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis.

Authors:  S Minoshima; K A Frey; N L Foster; D E Kuhl
Journal:  J Comput Assist Tomogr       Date:  1995 Jul-Aug       Impact factor: 1.826

10.  FDG PET and MRI in logopenic primary progressive aphasia versus dementia of the Alzheimer's type.

Authors:  Ajay Madhavan; Jennifer L Whitwell; Stephen D Weigand; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Nirubol Tosakulwong; Matthew L Senjem; Jeffrey L Gunter; Val J Lowe; Ronald C Petersen; Clifford R Jack; Keith A Josephs
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

View more
  69 in total

1.  Approach to atypical Alzheimer's disease and case studies of the major subtypes.

Authors:  Bradford C Dickerson; Scott M McGinnis; Chenjie Xia; Bruce H Price; Alireza Atri; Melissa E Murray; Mario F Mendez; David A Wolk
Journal:  CNS Spectr       Date:  2017-02-15       Impact factor: 3.790

2.  Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.

Authors:  Rik Ossenkoppele; Niklas Mattsson; Charlotte E Teunissen; Frederik Barkhof; Yolande Pijnenburg; Philip Scheltens; Wiesje M van der Flier; Gil D Rabinovici
Journal:  Neurobiol Aging       Date:  2015-04-25       Impact factor: 4.673

3.  Brain PET Poster Sessions PP01-M01 to PP02-N07.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2019-07       Impact factor: 6.200

4.  Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.

Authors:  Chenjie Xia; Sara J Makaretz; Christina Caso; Scott McGinnis; Stephen N Gomperts; Jorge Sepulcre; Teresa Gomez-Isla; Bradley T Hyman; Aaron Schultz; Neil Vasdev; Keith A Johnson; Bradford C Dickerson
Journal:  JAMA Neurol       Date:  2017-04-01       Impact factor: 18.302

5.  Scan-Time Corrections for 80-100-min Standardizetd Uptake Volume Ratios to Measure the 18F-AV-1451 Tracer for Tau Imaging.

Authors:  Mark He; Suzanne L Baker; Vyoma D Shah; Samuel N Lockhart; William J Jagust
Journal:  IEEE Trans Med Imaging       Date:  2018-09-17       Impact factor: 10.048

Review 6.  Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials.

Authors:  Jared R Brosch; Martin R Farlow; Shannon L Risacher; Liana G Apostolova
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 7.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

Review 8.  Posterior Cortical Atrophy.

Authors:  Jonathan M Schott; Sebastian J Crutch
Journal:  Continuum (Minneap Minn)       Date:  2019-02

Review 9.  Case Studies Illustrating Focal Alzheimer's, Fluent Aphasia, Late-Onset Memory Loss, and Rapid Dementia.

Authors:  Gamze Balci Camsari; Melissa E Murray; Neill R Graff-Radford
Journal:  Neurol Clin       Date:  2016-06-03       Impact factor: 3.806

10.  Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.

Authors:  Liang Wang; Tammie L Benzinger; Yi Su; Jon Christensen; Karl Friedrichsen; Patricia Aldea; Jonathan McConathy; Nigel J Cairns; Anne M Fagan; John C Morris; Beau M Ances
Journal:  JAMA Neurol       Date:  2016-09-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.